Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073587 · ClinicalTrials.gov registry record
The CARDIO-TTRansform Scintigraphy Sub-study
A clinical trial of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- 150
- Enrollment target
- 5
- Study locations
NCT06073587: Active study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
NCT06073587 is a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06073587, a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.
Primary Outcome
The Perugini grading scale visually compares tracer uptake in the myocardium and ribs following injection of the bone tracers (99mTc-DPD, 99mTc-Pyrophosphate \[PYP\], or 99mTc-HMDP). The scale includes 4 grade classifications: Grade 0- no cardiac uptake and normal rib uptake, Grade 1- cardiac uptake which is less than rib uptake, Grade 2- cardiac uptake with intensity similar rib uptake, and Grade 3- cardiac uptake greater than rib uptake with mild or absent rib uptake. Visual scores of 2 or gre
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Scintigraphy scan
Study Locations (5)
New York
- Columbia University Irving Medical Center - New York
North Carolina
- Duke University Medical Center - Durham
Ohio
- Cleveland Clinic Main Campus - Cleveland
Oregon
- Oregon Health and Science University - Portland
Other
- Hospital Universitario Puerta de Hierro - Majadahonda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2026-03 |
What the registry record for NCT06073587 still lists
NCT06073587 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 1 intervention - of which Scintigraphy scan is the first listed.
NCT06073587 lists 5 locations in 5 states (New York, North Carolina, Ohio).
Frequently Asked Questions
What is clinical trial NCT06073587 about?
NCT06073587 is a clinical study titled "The CARDIO-TTRansform Scintigraphy Sub-study". The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perug...
What is the current status of trial NCT06073587?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2023-04-04. Estimated completion is 2026-03.
What conditions does trial NCT06073587 study?
This clinical trial studies the following conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT06073587?
The interventions under investigation include: Scintigraphy scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06073587?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073587 being conducted?
This trial has 5 study locations across New York, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
ACTIVE NOT RECRUITING · Phase 3
-
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI